Biaoxue Rong1, Chongchong Zhao2, Hua Liu3, Zongjuan Ming1, Xiguang Cai3, Wenlong Gao4, Shuanying Yang1. 1. Department of Respiratory Medicine, Second Affiliated Hospital, Xi'an Jiaotong University Xi'an, China. 2. Department of Neurology, Lanzhou University Second Hospital Lanzhou, China. 3. Department of Respiratory Medicine, Gansu Provincial People's Hospital Lanzhou, China. 4. Departments of Statistics and Epidemiology, Medical College, Lanzhou University Lanzhou, China.
Abstract
BACKGROUND: Hsp90-beta was investigated as prognostic factor because of its apparent association with tumorigenesis. The aim of this study was to investigate the expression of Hsp90-beta in lung cancer patients, to analyze the relationship with respect to the clinicopathological features and to assess whether Hsp90-beta as a potential serum marker for lung cancer. METHODS: Expression of Hsp90-beta was examined using immunohistochemistry, in-situ hybridization, western blot and enzyme-linked immunosorbent assay. Sensitivities and specificities for Hsp90-beta serum test were determined using receiver operator characteristic curve and cutoff was defined based on 95% and 85% sensitivities. RESULTS: Lung cancer tissues exhibited higher expression of Hsp90-beta than the normal tissues (P < 0.05) and the serum Hsp90-beta of lung cancer patients also exhibited higher level than control groups (P < 0.05). Moreover, increased serum Hsp90-beta was significantly associated with the pathological grade and clinical stage of lung cancer patients (P < 0.05). Using receiver operator characteristic curve analysis, the cutoffs for distinguishing lung cancer from normal and benign groups were 1.155 and 1.158 ng/ml respectively. The sensitivities of Hsp90-beta for distinguishing lung cancer from normal and benign groups were 98.77% and 95.9%, and specificities were 88.33% and 72.7%. CONCLUSION: Up-regulation of serum Hsp90-beta was associated with pathological grade and clinical stage of lung cancer patients, which indicated that it could be considered molecular biomarker for diagnosis and prognosis of lung cancer.
BACKGROUND:Hsp90-beta was investigated as prognostic factor because of its apparent association with tumorigenesis. The aim of this study was to investigate the expression of Hsp90-beta in lung cancerpatients, to analyze the relationship with respect to the clinicopathological features and to assess whether Hsp90-beta as a potential serum marker for lung cancer. METHODS: Expression of Hsp90-beta was examined using immunohistochemistry, in-situ hybridization, western blot and enzyme-linked immunosorbent assay. Sensitivities and specificities for Hsp90-beta serum test were determined using receiver operator characteristic curve and cutoff was defined based on 95% and 85% sensitivities. RESULTS:Lung cancer tissues exhibited higher expression of Hsp90-beta than the normal tissues (P < 0.05) and the serum Hsp90-beta of lung cancerpatients also exhibited higher level than control groups (P < 0.05). Moreover, increased serum Hsp90-beta was significantly associated with the pathological grade and clinical stage of lung cancerpatients (P < 0.05). Using receiver operator characteristic curve analysis, the cutoffs for distinguishing lung cancer from normal and benign groups were 1.155 and 1.158 ng/ml respectively. The sensitivities of Hsp90-beta for distinguishing lung cancer from normal and benign groups were 98.77% and 95.9%, and specificities were 88.33% and 72.7%. CONCLUSION: Up-regulation of serum Hsp90-beta was associated with pathological grade and clinical stage of lung cancerpatients, which indicated that it could be considered molecular biomarker for diagnosis and prognosis of lung cancer.
Authors: Franziska Jahns; Anne Wilhelm; Karl Otto Greulich; Henning Mothes; Mariya Radeva; Anja Wölfert; Michael Glei Journal: Genes Nutr Date: 2011-10-19 Impact factor: 5.523
Authors: Susana Cedrés; Isaac Nuñez; Marina Longo; Pablo Martinez; Eva Checa; Davis Torrejón; Enriqueta Felip Journal: Clin Lung Cancer Date: 2011-04-24 Impact factor: 4.785
Authors: H Uozaki; T Ishida; C Kakiuchi; H Horiuchi; T Gotoh; T Iijima; T Imamura; R Machinami Journal: Pathol Res Pract Date: 2000 Impact factor: 3.250
Authors: Vishwaraj Sontake; Yunguan Wang; Rajesh K Kasam; Debora Sinner; Geereddy B Reddy; Anjaparavanda P Naren; Francis X McCormack; Eric S White; Anil G Jegga; Satish K Madala Journal: JCI Insight Date: 2017-02-23